SAN DIEGO, Jan. 06, 2017 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that the company will present at the Biotech Showcase™ at 4:00 PM Pacific Time (7:00 PM Eastern Time) on Tuesday, January 10, 2017. The presentation will take place in Room 3 (Ballroom Level) at the Hilton San Francisco Union Square.
Dr. Marc Hedrick, CEO and President of Cytori Therapeutics, will provide an update on current corporate activities and recent developments, including progress on its clinical pipeline.
A live audio webcast of the presentation will be available under the investor relations section of Cytori’s website at www.cytori.com. A replay of the presentation will be available for 90 days following the event. Please connect to Cytori’s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Biotech Showcase
The Biotech Showcase 2017 Conference (http://www.ebdgroup.com/bts/index.php) is one of the most significant healthcare investor conferences of the year. It is designed to provide private and public biotechnology and life sciences companies the opportunity to present to, and meet with, public and private investors, and pharmaceutical executives. This is the 9th year for the Biotech Showcase. More than 2100 investors and biopharmaceutical executives from around the world are expected to attend.
About Cytori
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit www.cytori.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts are forward looking statements. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. These risks and uncertainties are described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, included in our annual and quarterly reports.
There may be events in the future that we are unable to predict, or over which we have no control, and our business, financial condition, results of operations and prospects may change in the future. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless we have an obligation under U.S. Federal securities laws to do so.
Cytori Therapeutics, Inc. Tiago Girao, +1 (858) 458.0900 [email protected]


CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Apple Turns 50: From Garage Startup to AI Crossroads
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 



